文献速递乳腺癌

1990-2023年全球女性乳腺癌负担及2050年预测:GBD 2023系统分析

Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
PubMed 文献 · Lancet Oncol · 2026-01-01

基于GBD 2023,分析1990-2023年204个国家女性乳腺癌发病率、死亡率、DALYs及七类风险因素归因负担,并预测至2050年。

核心结论

  • 高收入国家乳腺癌发病率稳定、死亡率下降,反映筛查、诊断和治疗成效。
  • 其他地区发病率与死亡率同步上升,提示卫生系统存在缺陷。

研究设计与样本

  • GBD 2023系统分析,估算1990-2023年204个国家和地区女性乳腺癌发病、死亡、患病、YLDs、YLLs和DALYs。
  • 死亡估计采用GBD死因集合模型,整合人群癌症登记、生命登记和口头尸检数据。
  • 通过死亡率-发病率比推算发病估计,患病率为发病与模型生存估计的组合。
  • 归因负担采用比较风险评估框架分析七类风险因素。
  • 使用GBD预测框架预测2024-2050年发病和死亡,年龄标化率基于GBD 2023世界标准人口。

临床怎么用

  • 应关注低收入和中等收入地区乳腺癌发病与死亡率同步上升趋势,加强筛查、早期诊断和治疗可及性。
  • 高收入国家ASMR下降经验支持筛查与治疗综合干预的有效性。
  • 饮食风险、烟草和高空腹血糖是需重点干预的可归因风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer is a leading cause of mortality and morbidity among females worldwide. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, we provided an updated comprehensive assessment of the epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally from 1990 to 2023. METHODS: Breast cancer incidence, mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) were estimated by age and sex for 204 countries and territories from 1990 to 2023. Mortality estimates were generated using GBD Cause of Death Ensemble models, leveraging data from population-based cancer registration systems, vital registration systems, and verbal autopsies. Mortality-to-incidence ratios were calculated to derive both mortality and incidence estimates. Prevalence was calculated by combining incidence and modelled survival estimates. YLLs were established by multiplying age-specific deaths with the GBD standard life expectancy at the age of death. YLDs were estimated by applying disability weights to prevalence estimates. The sum of YLLs and YLDs equalled the number of DALYs. Breast cancer burden attributable to seven risk factors was examined through the comparative risk assessment framework. The GBD forecasting framework was used to forecast breast cancer incidence and mortality from 2024 to 2050. Age-standardised rates were calculated for each metric using the GBD 2023 world standard population. FINDINGS: In 2023, there were an estimated 2·30 million (95% uncertainty interval [UI] 2·01 to 2·61) breast cancer incident cases, 764 000 deaths (672 000 to 854 000), and 24·1 million (21·3 to 27·5) DALYs among females globally. In the World Bank low-income group, where a low age-standardised incidence rate (ASIR) was estimated (44·2 per 100 000 person-years [31·2 to 58·4]), the age-standardised mortality rate (ASMR) was the highest (24·1 per 100 000 [16·8 to 31·9]). The highest ASIR was in the high-income group (75·7 per 100 000 [67·1 to 84·0]), and the lowest ASMR was in the upper-middle-income group (11·2 per 100 000 [10·2 to 12·3]). Between 1990 and 2023, the ASIR in the low-income group increased by 147·2% (38·1 to 271·7), compared with a 1·2% (-11·5 to 17·2) change in the high-income group. The ASMR decreased in the high-income group, changing by -29·9% (-33·6 to -25·9), but increased by 99·3% (12·5 to 202·9) in the low-income group. The increase in age-standardised DALY rates followed that of ASMRs. Risk factors such as dietary risks, tobacco use, and high fasting plasma glucose contributed to 28·3% (16·6 to 38·9) of breast cancer DALYs in 2023. The risk factors with a decrease in attributable DALYs between 1990 and 2023 were high alcohol use and tobacco. By 2050, the global incident cases of breast cancer among females were forecast to reach 3·56 million (2·29 to 4·83), with 1·37 million (0·841 to 2·02) deaths. INTERPRETATION: The stable incidence and declining mortality rates of female breast cancer in high-income nations reflect success in screening, diagnosis, and treatment. In contrast, the concurrent rise in incidence and mortality in other regions signals health system deficits. Without effective interventions, many countries will fall short of the WHO Global Breast Cancer Initiative's ambitious target of achieving an annual reduction of 2·5% in age-standardised mortality rates by 2040. The mounting breast cancer burden, disproportionately affecting some of the world's most vulnerable populations, will further exacerbate health inequalities across the globe without decisive immediate action. FUNDING: Gates Foundation, St Jude Children's Research Hospital.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Oncol. 2026. PMID: 41785894. doi:10.1016/S1470-2045(25)00730-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。